Gilead Sciences Inc (GILD)

pos +0.00
Today's Range: 0.00 - 0.00 | GILD Avg Daily Volume: 11,104,200
Last Update: 11/24/15 - 3:59 PM EST
Volume: 0
YTD Performance: 13.06%
Open: $0.00
Previous Close: $106.57
52 Week Range: $85.95 - $123.37
Oustanding Shares: 1,441,180,186
Market Cap: 153,283,924,583
6-Month Chart
TheStreet Ratings Grade for GILD
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 9 9 10 11
Moderate Buy 2 2 3 3
Hold 3 3 2 1
Moderate Sell 1 1 1 1
Strong Sell 0 0 0 0
Mean Rec. 1.73 1.73 1.59 1.47
Latest Dividend: 0.43
Latest Dividend Yield: 1.62%
Dividend Ex-Date: 12/14/15
Price Earnings Ratio: 9.76
Price Earnings Comparisons:
GILD Sector Avg. S&P 500
9.76 9.80 32.53
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
5.88% 5.93% 180.01%
Revenue 122.20 1.97 0.43
Net Income 294.40 3.32 0.62
EPS 305.00 3.39 0.63
Earnings for GILD:
Revenue 24.89B
Average Earnings Estimates
Qtr (12/15) Qtr (03/16) FY (12/15) FY (12/16)
Average Estimate $2.88 $2.76 $11.96 $11.68
Number of Analysts 5 3 5 5
High Estimate $3.05 $2.88 $12.20 $12.58
Low Estimate $2.80 $2.63 $11.73 $10.59
Prior Year $2.38 $2.89 $7.91 $11.96
Growth Rate (Year over Year) 21.18% -4.50% 51.25% -2.37%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
The sector saw solid performance this week as the biotech juggernaut mounted a long-overdue rally.

Gilead Leads a Biotech Rally Real Money Pro($)

The sector saw solid performance this week as the biotech juggernaut mounted a long-overdue rally.
Apple tops the list, but it has lots of company.
For upside, there is clear resistance at $110.
AbbVie, Teva and Zimmer Biomet posted solid quarters and are upbeat about the road ahead.
Here are some mid-cap names with solid upside potential.
Consensus earnings estimates are just too high.
Gilead Sciences, Merck and Pfizer offer healthy prospects at attractive prices.

Thank God It's Friday! Real Money Pro($)

Good morning! Bret Jensen here.
These names are getting no respect despite solid news and growth prospects.

Columnist Conversations

"Valuations on both the asset markets and the housing market in particular are unusually high at present. This...
Market holding up very well given news of downed Russian jet over Turkey today. However, it is still a very b...
Yesterday's Saudi announcement coupled with this morning's geopolitical tensions have combined to goose oil pr...
These refiners are stretching out here, the best turnover is in Valero, and we have seen some big option flow ...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.